Jaime A. Davidson, MD   is a consultant for, on the advisory board of, and/or on the speakers bureau of Abbott Laboratories, Animas Corporation, AstraZeneca, Bristol-Myers Squibb, Cure-DM, Inc, Eli Lilly and Company, Generex Biotechnology Corporation, GlaxoSmithKline, Johnson & Johnson (LifeScan), Merck Serono, Merck Sharp & Dohme Corporation, Novo Nordisk Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation, Pfizer, Inc, Roche Pharmaceuticals, sanofi-aventis, and Takeda Pharmaceutical Company, Ltd.

Zachary Bloomgarden, MD   has received salary/honoraria from Amylin Pharmaceuticals, Inc, Daiichi Sankyo Company, Limited, Eli Lilly and Company, GlaxoSmithKline, Inc, Merck & Co, Inc, and Novo Nordisk, Inc; has received consulting fees from AstraZeneca, AtheroGenics, Inc, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo Company, Limited, Dainippon Sumitomo Pharma America, Inc, Forest Laboratories, Inc, Medtronic, Inc, Merck & Co, Inc., Nastech Pharmaceutical Company, Novartis Pharmaceuticals Corporation, and Takeda Pharmaceutical Company Limited; and has ownership interest in Abbott Laboratories, Bard, Inc, Hoffmann-La Roche Inc, Medtronic, Inc, Merck & Co, Inc, Millipore, and Novartis Pharmaceuticals Corporation.

Mark E. Molitch, MD   has received consulting fees from Abbott Laboratories, Corcept Therapeutics, and Novartis Pharmaceuticals Corporation; and has performed contracted research for Corcept Therapeutics and Novartis Pharmaceuticals Corporation.

Charles Reasner, MD   has received salary/honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Novo Nordisk Pharmaceuticals, Inc, and Takeda Pharmaceutical Company Limited.